AIMS
New-onset diabetes (NoD) is a recognised effect of statin therapy potentially influencing acceptance of intensive LDL-C-lowering. In contrast, cholesteryl ester transfer protein (CETP) inhibition has been associated with lower NoD risk in earlier trials. We assessed the effect of the highly selective CETP inhibito...
J. Brandts, M. Szarek, S. J. Nicholls et al.· European Journal of Preventi...· 0 citations
Atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) impact health and healthcare systems. Inflammation is a potential modifiable risk factor for both conditions. The case for evaluating the modification of inflammation in these conditions could be strengthened by evidence that systemic...
Kausik K. Ray, Fotis Barkas, E. Huisman et al.· European Heart Journal Open· 0 citations
BACKGROUND
Distal symmetrical polyneuropathy (DSPN) is a prevalent complication of diabetes, with emerging evidence of onset in earlier stages of dysglycemia. Prediabetes is characterized by insulin resistance, central adiposity, and dyslipidemia. Data on the incidence of DSPN in prediabetes and possible association wi...
Georgia Anastasiou, Nikoloas Papanas, Fotis Barkas et al.· Diabetes Research and Clinic...· 0 citations
Current evidence on the pathophysiological mechanisms underlying CKM-related dyslipidaemia is examined and a practical framework for its assessment and management is provided to provide a practical framework for its assessment and management.
A. Ceasovschih, Y. Şener, M. Arici et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.